BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36370168)

  • 21. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.
    Sugawara E; Togashi Y; Kuroda N; Sakata S; Hatano S; Asaka R; Yuasa T; Yonese J; Kitagawa M; Mano H; Ishikawa Y; Takeuchi K
    Cancer; 2012 Sep; 118(18):4427-36. PubMed ID: 22252991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
    Moch H; Amin MB; Berney DM; Compérat EM; Gill AJ; Hartmann A; Menon S; Raspollini MR; Rubin MA; Srigley JR; Hoon Tan P; Tickoo SK; Tsuzuki T; Turajlic S; Cree I; Netto GJ
    Eur Urol; 2022 Nov; 82(5):458-468. PubMed ID: 35853783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
    Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translocation carcinomas of the kidney.
    Argani P
    Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody.
    Taheri D; Zahavi DJ; Del Carmen Rodriguez M; Meliti A; Rezaee N; Yonescu R; Ricardo BF; Dolatkhah S; Ning Y; Bishop JA; Netto GJ; Sharma R
    Virchows Arch; 2016 Sep; 469(3):345-50. PubMed ID: 27271275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of anaplastic lymphoma kinase fusions in clear cell renal cell carcinoma.
    Chen W; Li W; Bai B; Wei H
    Oncol Rep; 2020 Mar; 43(3):817-826. PubMed ID: 32020234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances of immunohistochemistry for diagnosis of renal tumors.
    Kuroda N; Tanaka A; Ohe C; Nagashima Y
    Pathol Int; 2013 Aug; 63(8):381-90. PubMed ID: 23957913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy?
    Smith NE; Deyrup AT; Mariño-Enriquez A; Fletcher JA; Bridge JA; Illei PB; Netto GJ; Argani P
    Am J Surg Pathol; 2014 Jun; 38(6):858-63. PubMed ID: 24698962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights in the new WHO classification of adult renal tumors.
    Hes O; Michalová K; Pivovarčíková K
    Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
    van der Krogt JA; Bempt MV; Ferreiro JF; Mentens N; Jacobs K; Pluys U; Doms K; Geerdens E; Uyttebroeck A; Pierre P; Michaux L; Devos T; Vandenberghe P; Tousseyn T; Cools J; Wlodarska I
    Haematologica; 2017 Sep; 102(9):1605-1616. PubMed ID: 28659337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploration of clinicopathological features of rearranged renal cell carcinoma and TFE3, TFEB, and ALK staining performance in renal entities.
    Liu Y; Li X; Fan Y; Xu H; Gu Y; Dong L; Zhou L; Yang X; Wang C
    Heliyon; 2023 Apr; 9(4):e15159. PubMed ID: 37089387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
    Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
    [No Abstract]   [Full Text] [Related]  

  • 33. [Renal cell carcinoma with t(6;11)(p21.2;q13)/MALAT1-TFEB fusion: a clinical and pathological analysis].
    Xia Q; Shi S; Shen Q; Wei X; Wang X; Ma H; Lu Z; Zhou X; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):895-9. PubMed ID: 26888508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene.
    Kusano H; Togashi Y; Akiba J; Moriya F; Baba K; Matsuzaki N; Yuba Y; Shiraishi Y; Kanamaru H; Kuroda N; Sakata S; Takeuchi K; Yano H
    Am J Surg Pathol; 2016 Jun; 40(6):761-9. PubMed ID: 26848800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of Anaplastic Lymphoma Kinase Gene Re-Arrangement in Non-Small Cell Lung Carcinoma in the Indian Population: Comparison of Techniques and Immunohistochemistry Clones.
    Shukla S; Pandey RK; Kant S; Garg R; Anand N; Kushwaha R; Malhotra KP; Srivastava A; Bhatt M; Husain N
    Turk Patoloji Derg; 2019; 35(1):36-45. PubMed ID: 30596395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
    Kato I; Furuya M; Baba M; Kameda Y; Yasuda M; Nishimoto K; Oyama M; Yamasaki T; Ogawa O; Niino H; Nakaigawa N; Yano Y; Sakamoto K; Urata Y; Mikami K; Yamasaki S; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Histopathology; 2019 Aug; 75(2):254-265. PubMed ID: 30908700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study.
    Bironzo P; Melocchi L; Monica V; Trebeschi D; Barbieri F; Maiello E; Migliorino MR; Lombardi A; Tiseo M; Righi L; Graziano P; Rossi G; Novello S
    Pathologica; 2022 Aug; 114(4):278-287. PubMed ID: 36083243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
    Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.